article · Journal of Medical and Life Science
Lung cancer persistently poses as a primary factor in cancer-linked deaths globally, necessitating novel treatment strategies. This investigation appraises the anti-tumor potential of Thymoquinone (TQ) and 1,3,4-oxadiazole derivatives independently and jointly against lung malignancy. immunohistochemical (IHC) analysis exhibited meaningful alteration of Bcl-2, CD4, and CD8 manifestation, signifying heightened apoptosis and immune response. Molecular studies demonstrated the compounds' ability to adjust key genes involved in cancer development, specifically Caspase-1 and mTOR pathways. The combined therapy exhibited synergistic impacts, suggesting a promising approach for lung cancer management. These conclusions highlight the potential of TQ and 1,3,4-oxadiazole as effective therapeutic agents, warranting further clinical exploration and research.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.21608/jmals.2024.410841
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.